Diversify Wealth Management LLC Buys 2,924 Shares of Ascendis Pharma A/S $ASND

Diversify Wealth Management LLC boosted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 37.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,675 shares of the biotechnology company’s stock after acquiring an additional 2,924 shares during the period. Diversify Wealth Management LLC’s holdings in Ascendis Pharma A/S were worth $2,352,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ASND. Rhumbline Advisers boosted its position in shares of Ascendis Pharma A/S by 4.0% in the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 55 shares during the period. Certuity LLC raised its position in shares of Ascendis Pharma A/S by 5.7% during the 4th quarter. Certuity LLC now owns 1,170 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 63 shares during the period. Personal CFO Solutions LLC raised its position in shares of Ascendis Pharma A/S by 4.4% during the 1st quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 64 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Ascendis Pharma A/S by 15.1% during the 4th quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 72 shares in the last quarter. Finally, New Wave Wealth Advisors LLC lifted its stake in shares of Ascendis Pharma A/S by 3.7% during the 4th quarter. New Wave Wealth Advisors LLC now owns 2,518 shares of the biotechnology company’s stock valued at $537,000 after buying an additional 89 shares in the last quarter.

Ascendis Pharma A/S Trading Down 1.9%

ASND stock opened at $265.22 on Tuesday. The firm has a fifty day moving average price of $240.71 and a 200 day moving average price of $230.69. Ascendis Pharma A/S has a fifty-two week low of $160.86 and a fifty-two week high of $282.15. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The firm has a market cap of $16.54 billion, a PE ratio of 30.59 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post 4.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Ascendis Pharma A/S news, insider Flemming Steen Jensen sold 19,460 shares of Ascendis Pharma A/S stock in a transaction on Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the acquisition, the director owned 400 shares in the company, valued at approximately $95,120. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 40.00% of the company’s stock.

Wall Street Analysts Forecast Growth

ASND has been the subject of a number of analyst reports. Evercore reiterated an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Jefferies Financial Group assumed coverage on Ascendis Pharma A/S in a research report on Monday, March 16th. They issued a “buy” rating and a $290.00 price objective on the stock. Barclays boosted their price objective on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Wells Fargo & Company dropped their price objective on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Saturday, July 4th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Buy” and an average target price of $295.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.